BiotechTV

𝐁𝐞𝐡𝐢𝐧𝐝 𝐭𝐡𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞: Entos Pharmaceuticals' founder John Lewis discusses trying to design a delivery vehicle that's better than AAV and LNPs by harnessing fusogens. He describes the limitations of AAV and LNPs, and how the Entos construct is meant overcome them. Plus, a summary of the company's pipeline, which includes obesity, cystic fibrosis, ocular diseases, and more. Full video: https://lnkd.in/gbJmp3-M BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

𝐅𝐫𝐨𝐦 𝐁𝐚𝐫𝐜𝐞𝐥𝐨𝐧𝐚: Previewing #ESMO24 with oncology watcher DELSUC Bertrand. He highlights things to watch at this year's conference such as PD1xVEGF, PRMT5, TIGIT, and numerous ADCs. Full video: https://lnkd.in/gzFWWGQ4 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐓𝐡𝐮𝐫𝐬𝐝𝐚𝐲𝐬: HSBC's Rajesh Kumar joins BiotechTV for Analyst Thursdays and talks PD-1xVEGF, obesity, European conglomerates, and more. Rajesh Kumar, HSBC's head of life sciences and healthcare equity research in London, talks Merck, Roche, Novo Nordisk, Lilly, Bayer, and Merck KGaA. Full video: https://lnkd.in/ggDY3wgK BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

𝐅𝐫𝐨𝐦 𝐃𝐚𝐫𝐦𝐬𝐭𝐚𝐝𝐭: Merck Group's head of global R&D and CMO Danny Bar-Zohar gives an overview of the company's programs and its appetite for business development He describes Merck KGaA's three pillars of healthcare research: oncology, neurology, and immunology. Plus, the advantages of the company's heritageand location in Germany. Full video: https://lnkd.in/gkPckJbX BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

𝐁𝐫𝐢𝐠𝐡𝐭 𝐌𝐢𝐧𝐝𝐬: Biotech expert Dirk Haussecker shares his opinion on the various emerging technology platforms in genetic medicine. Known widely as RNAiAnalyst on twitter, he discusses antisense, RNAi, CRISPR, base editing, ADAR, splicing, and more. Full video: https://lnkd.in/eqgGDum3 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐢𝐧𝐠 𝐍𝐞𝐰𝐬: London's Epsilogen Ltd completed a £12.5 million Series B expansion this week to take its IgE based folate receptor alpha program into a phase 1b study. CEO Tim Wilson describes the rationale for focusing on IgE, and why the company has chosen folate receptor alpha as its first target. This new fundraising brings total series B funds raised to £43.25 million. Full video: https://lnkd.in/gcqEvPT9 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: The Co-CEOs of Summit Therapeutics, Inc. discuss the ivonescimab vs Keytruda data that was presented at the 2024 World Conference on Lung Cancer. Bob Duggan and Dr. Maky Zanganeh answer questions relating to China derived data, designing U.S. studies, how to scale the development of the drug, and more. Full video: https://lnkd.in/gAv8xMxJ BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

𝐅𝐫𝐨𝐦 𝐁𝐞𝐫𝐥𝐢𝐧: T-knife Therapeutics is carrying on the tradition of German leadership in TCR based technologies in oncology. CEO Tom Soloway and CTO Elisa Kieback walk us through what makes T-knife unique in the construction and manufacturing of its cell therapies, and how they are readying to enter the clinic in PRAME. Full video: https://lnkd.in/gcqfwxcw BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

𝐍𝐞𝐰: Introducing the BiotechTV video podcast studio at MassBio in Kendall Square. The Studio has been built for you, the expert biotech community in Boston. You be the host, nominate a guest, and send us your idea. Record in studio and we'll broadcast it to our audience on BiotechTV. Topics could be things such as: recent news analysis, discussions about technologies in development, newsworthy scientific papers, patient perspectives, conference previews, regulatory issues, company creation, and more. Your creativity is welcome. BiotechTV would like to thank Kendalle Burlin O'Connell, Esq. and MassBio for supporting this idea and making their space on 'The Most Innovative Square Mile on the Planet' available for it. Together, we have built this to give a greater voice to the amazing experts in this incredible area. Below is a link to the dedicated page on BiotechTV where these episodes will live. Please reach out to the contact info listed on the page if you would like to host a biotech discussion at The Studio at Kendall Square! https://lnkd.in/giysXQMP

𝐅𝐫𝐨𝐦 𝐁𝐞𝐫𝐥𝐢𝐧: Andreas Eckert, founder of Eckert & Ziegler SE, is an expert in radio isotopes and how they are used in medicine. A subsidiary, Pentixapharm AG, is about to be spun off into is own public company. From Berlin, he describes the various isotopes that are used in medicines and discusses the technological advances that have lead to a surge of success and activity in this field. Full video: https://lnkd.in/g-UKrvY5 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent